Breaking News

BioNTech SE Completes Plasmid DNA Manufacturing Facility in Marburg, Germany

Will independently manufacture the majority of its own current regular demand for DNA plasmids in the new manufacturing facility.

Author Image

By: Charlie Sternberg

Associate Editor

BioNTech SE has completed construction of the company’s first proprietary plasmid DNA manufacturing facility in Marburg, Germany.   Plasmid DNA is an important starting material for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies. With the new facility, BioNTech plans to independently manufacture plasmid DNA for clinical product candidates and commercial products in the areas of cancer and infectious diseases.   BioNTech plans to independently manufacture th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters